Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CEST
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
08/17 JOUNCE THERAPEUTICS : Names Hugh Cole as Chief Business Officer and Head of Corp..
08/16 JOUNCE THERAPEUTICS : Names Hugh Cole as Chief Business Officer and Head of Corp..
08/16 SHIRE : eye drug nears approval across Europe
08/15 SHIRE : announces submission of lifitegrast Marketing Authorization Application ..
08/12 SHIRE : Provision of exclusive pharmaceutical products from Shire Pharmaceutical..
08/09 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
08/09DJSHIRE PLC SHIRE PLC : Director/Pdmr Shareholding
08/09 SHIRE : shifts vaccine facility from Baxalta deal to MSD
08/04 British stocks up 0.85 pct Thursday
08/04 SHIRE : Half-yearly Report
More news
News from SeekingAlpha
08/18 Shire PLC 2017 Q2 - Results - Earnings Call Slides
08/18 Tracking John Paulson's Paulson & Company Portfolio - Q2 2017 Update
08/17 Evercore ISI initiates 14 bullish calls, 9 neutral
08/15 Shire submits marketing application in Europe for lifitegrast for dry eye dis..
08/14 CTI BIOPHARMA'S PACRITINIB : Where We Stand Today
Financials ($)
Sales 2017 15 028 M
EBIT 2017 5 499 M
Net income 2017 2 641 M
Debt 2017 18 745 M
Yield 2017 0,74%
P/E ratio 2017 16,05
P/E ratio 2018 11,54
EV / Sales 2017 4,17x
EV / Sales 2018 3,74x
Capitalization 43 974 M
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 69,8 $
Spread / Average Target 44%
EPS Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-19.63%43 974
JOHNSON & JOHNSON15.12%357 079
ROCHE HOLDING LTD.4.99%218 752
NOVARTIS8.84%218 545
PFIZER0.59%196 221